NervGen Pharma opened higher at $1.38, compared with its previous close of $1.35. In the last trading session, the stock traded between $1.36 and $1.63. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in NervGen Pharma is now worth
$ 27.15
Resulting in a loss of
$ 72.85 (72.85%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.27 (+20.07%)
Day High
$1.63
Day Low
$1.36
Day Open
$1.38
Prev Close
$1.35
Volume
24,91,057
1W Return
20.97%
1M Return
-5.81%
3M Return
-6.41%
6M Return
-57.68%
1Y Return
-72.85%
Fundamentals
Market Cap ($ Mn)
174
PE Ratio
-
PB Ratio
19.96
PEG Ratio
-
ROE
-6,156.67%
ROCE
-6,188.74%
EPS (TTM)
$-0.02
Investment Returns
1 Week
20.97%
1 Month
-5.81%
3 Months
-6.41%
6 Months
-57.68%
9 Months
-60.46%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
Updates
12Nov
NervGen gets FDA breakthrough therapy designation for SCI drug
FDA grants Breakthrough Therapy designation to NervGen's NVG-291 for chronic SCI. Designation based on Phase 1b/2a CONNECT SCI study showing functional hand use improvements. Phase 3 RESTORE study currently enrolling approximately 150 participants in US and Canada. No serious adverse events or treatment discontinuations reported in preliminary data.
Today
26Sep
NervGen to restate FY25 and Q2FY26 financials on warrant adjustments
NervGen will restate FY25 and Q2FY26 financial statements due to warrant valuation revisions. Adjustments are non-cash, reducing stock-based compensation expense and warrant liabilities. No impact on cash and cash equivalents, cash runway, or business operations. Company remains on track to report Q3FY26 financial results.
1mo ago
14Jul
HC Wainwright maintains Buy on NervGen Pharma, cuts target
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a Buy rating for NervGen Pharma but lowered the price target to $15 from $18. This follows earlier coverage by Leerink Partners, which had initiated the stock with an Outperform rating and a $10 target.
